CareDx, Inc
NASDAQ:CDNAMedical - Diagnostics & Research
+$1.19 today
- Market cap
- $3.91B
- Beta
- 2.48
- P/E (TTM)
- -154.0
- EPS (TTM)
- -$0.16
Volume 0.54M
Average 0.74M
CDNA Common Stock Issued
Cash raised by issuing new shares.
CareDx, IncNASDAQ: CDNA
Common Stock Issued · Q2 FY2026 · quarter ended Jun 2026
Common stock issued outflow grows to $2.75M
Q2 FY2026 common stock issued was $2.75M, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $5.5M.
Context
- Common stock issued amounted to 2.1% of revenue in FY2025, up 2.1 pp from a year earlier.
- Common stock issued increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly common stock issued holds near $2.75M or moves back toward the trailing-twelve-month quarterly average of $1.37M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 8M USD
- Year-over-year change
- —
- 4-year CAGR
- -54.6%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 188.86M | — |
Common Stock Issued vs competitors
How CDNA compares with its peers on the latest reported figures
- CDNA's LTM Jun 2026 common stock issued of $5.5M is the 5th largest of the 8 companies compared; the peer median is $3.3M.
- Its year-over-year change of -59.6% is the 2nd highest of 3, against a peer median of -3.8%.
- Common stock issued amounts to 1.2% of revenue for CDNA, versus a peer median of 2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BLLNBillionToOne, Inc. | LTM Jun 2026 | $297.55M | — | — | 74.9% |
| LTM Jun 2026 | $55.4M | +113.9% | -52.8% | 2.0% | |
| LTM Jun 2026 | $20.47M | — | — | 3.6% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $13.44M | -121.6% | -36.1% | 3.0% |
| LTM Jun 2026 | $5.5M | -59.6% | — | 1.2% | |
| LTM Mar 2026 | $3.3M | — | — | 0.4% | |
| LTM Mar 2026 | $9K | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CDNA) | $3.3M | -3.8% | -44.4% | 2.0% | |
Competitors are the stored peer set for CDNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.66M) | (76.61M) | (190.28M) | 52.55M | (21.35M) |
| Depreciation & Amortization | 11.89M | 16.01M | 19.82M | 19.76M | 20.42M |
| Deferred Income Tax | 0 | 0 | 566K | (187K) | 17K |
| Stock-Based Compensation | 36.08M | 46.55M | 49.09M | 66.41M | 34.86M |
| Change in Working Capital | (40.97M) | (14.22M) | 106.03M | (102.31M) | 3.81M |
| Accounts Receivables | (24.42M) | (6.66M) | 16.02M | (13.74M) | 22.52M |
| Inventory | (6.93M) | (2.86M) | 54K | (1.02M) | (4.96M) |
| Accounts Payables | 1.79M | (2.05M) | 2.9M | (5.11M) | 808K |
| Other Working Capital | (11.42M) | (2.64M) | 87.06M | (82.44M) | (14.56M) |
| Other Non-Cash Items | 4.37M | 3.03M | (3.61M) | 1.83M | 4.28M |
| Operating Cash Flow | (19.29M) | (25.24M) | (18.39M) | 38.05M | 42.03M |
| Capital Expenditures | (20.26M) | (24.33M) | (9.24M) | (6.48M) | (5.91M) |
| Acquisitions (Net) | (15.43M) | (610K) | (6.68M) | 0 | 0 |
| Purchases of Investments | (5.5M) | (315.15M) | (201.17M) | (160.29M) | (145.93M) |
| Sales of Investments | 88.91M | 111.59M | 256.04M | 166.92M | 154.67M |
| Other Investing Activities | 0 | 0 | 1.5M | (634K) | 0 |
| Investing Cash Flow | 47.71M | (228.5M) | 40.45M | (483K) | 2.16M |
| Debt Repayment | (66K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 188.86M | 0 | 0 | 0 | 8M |
| Common Stock Repurchased | 0 | (642K) | (27.54M) | (522K) | (87.77M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.15M) | (3.89M) | (2.07M) | (5.08M) | (13.62M) |
| Financing Cash Flow | 185.64M | (4.54M) | (29.61M) | (5.61M) | (93.39M) |
| Effect of Forex Changes | (303K) | 23K | (112K) | 532K | (90K) |
| Net Change in Cash | 213.76M | (258.25M) | (7.66M) | 32.49M | (49.29M) |
| Free Cash Flow | (39.55M) | (49.57M) | (27.63M) | 31.56M | 36.12M |
CareDx, Inc
NASDAQ:CDNA
Intrinsic Alpha fair value
Locked
Current Price
$74.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.